Effects of chronic bryostatin-1 on treatment-resistant depression in rats

被引:9
作者
Alkon, Daniel L. [2 ]
Hongpaisan, Jarin [1 ]
Sun, Miao-Kun [1 ]
机构
[1] Blanchette Rockefeller Neurosci Inst, 8 Med Ctr Dr, Morgantown, WV 26505 USA
[2] NeuroDiagnost LLC, Rockville, MD USA
关键词
Bryostatin; 1; Depression; Refractory depression; Spatial learning and memory; ANTIDEPRESSANT ACTIVITY; CLINICAL-PRACTICE; MAJOR DEPRESSION; ANIMAL-MODELS; MEMORY; THERAPEUTICS; DISORDERS; BEHAVIOR; KETAMINE; TRIALS;
D O I
10.1016/j.ejphar.2017.05.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite over a half-century's intensive research worldwide, the currently available antidepressants remain suboptimal. Therapeutic options for treatment-resistant depression, for instance, are rather limited. Here, we found that rats exhibited a lasting treatment-resistant depressive immobility in response to open space swim test at a high intensity of induction. The induced depressive behavior is associated with a dramatic impairment in spatial learning and memory. Both the depressive immobility and impairment in spatial learning and memory are sensitive to a period of chronic treatment with bryopstatin-1, a relatively selective activator of protein kinase C epsilon. Bryostatin-1-like analogues therefore might have therapeutic values for the treatment of treatment-resistant depression.
引用
收藏
页码:71 / 74
页数:4
相关论文
共 50 条
  • [21] Intranasal esketamine for treatment-resistant depression
    Sobieraj, A.
    Wang, E.
    Kohl, P.
    Kirsch, B.
    Slapakova, L.
    Schuele, C.
    Falkai, P.
    EUROPEAN PSYCHIATRY, 2020, 63 : S117 - S117
  • [22] Prevalence and management of treatment-resistant depression
    Nemeroff, Charles B.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 : 17 - 25
  • [23] New paradigms for treatment-resistant depression
    Zarate, Carlos
    Duman, Ronald S.
    Liu, Guosong
    Sartori, Simone
    Quiroz, Jorge
    Murck, Harald
    ANNALS REPORTS, 2013, 1292 : 21 - 31
  • [24] Relationships Among Neurocognition, Symptoms, and Functioning in Treatment-Resistant Depression
    Gupta, Maya
    Holshausen, Katherine
    Best, Michael W.
    Jokic, Ruzica
    Milev, Roumen
    Bernard, Theresa
    Gou, Lisa
    Bowie, Christopher R.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2013, 28 (03) : 272 - 281
  • [25] Choosing Medications for Treatment-Resistant Depression Based on Mechanism of Action
    Thase, Michael E.
    Schwartz, Thomas L.
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (06) : 720 - 727
  • [26] Treatment-resistant depression increases health costs and resource utilization
    Lepine, Beatrice Alinka
    Moreno, Ricardo Alberto
    Campos, Rodolfo Nunes
    Couttolenc, Bernard Francois
    REVISTA BRASILEIRA DE PSIQUIATRIA, 2012, 34 (04) : 379 - 388
  • [27] Treatment-Resistant Depression: An Overview
    Moukaddam, Nidal
    Shah, Asim A.
    PSYCHIATRIC ANNALS, 2016, 46 (04) : 224 - 229
  • [28] Psychotherapy and Treatment-Resistant Depression
    Parks, Kimberly
    Wojcik, Katharine D.
    Blassingame, Jonathan C., III
    PSYCHIATRIC ANNALS, 2024, 54 (06) : e182 - e185
  • [29] Chronotherapy in Treatment-Resistant Depression
    Casher, Michael I.
    Schuldt, Stephen
    Haq, Aazaz
    Burkhead-Weiner, Davita
    PSYCHIATRIC ANNALS, 2012, 42 (05) : 166 - 169
  • [30] Metyrapone in treatment-resistant depression
    Sigalas, Paul David
    Garg, Himanshu
    Watson, Stuart
    McAllister-Williams, Richard Hamish
    Ferrier, I. Nicol
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2012, 2 (04) : 139 - 149